COVID-19 | Updated Regularly

From the onset of the novel coronavirus outbreak, QIAGEN has responded to the needs of healthcare workers and scientists who are working tirelessly to help conquer the virus. Latest information on this global mission below.

Background information on QIAGEN solutions, the coronavirus, and how coronavirus testing works available here (Updated May 27th).

Featured

Ensuring critical deliveries when every minute counts

UPS teams up with QIAGEN to deliver coronavirus testing solutions to curb the SARS-CoV-2 pandemic.

Emergency protocols

Supporting healthcare workers around the world in the fight against COVID-19

QIAGEN supports several testing protocols by providing test components, mid- to high-throughput automation solutions, and a multiplex syndromic detection solution. We also support scientists seeking to better understand the SARS-CoV-2 virus with research tools, including sequencing components and tools for data analysis and interpretation. We will continue to work tirelessly on novel approaches.

QIAGEN support in current testing protocols for emergency use

Product availability varies by country. Please contact your country representative or complete the support request form for further details. Please also review the protocols themselves for alternative solutions from other suppliers.

Testing

RNA extraction

Given the current public health emergency with COVID-19, QIAGEN and other companies are facing unprecedented demand for viral RNA isolation solutions. QIAGEN has developed dedicated solutions for viral RNA isolation that have been optimized for maximum sensitivity and reproducibility. We recognize that currently, scientists are seeking to use various QIAGEN kits, such as RNeasy, for SARS-CoV-2 RNA isolation from respiratory samples. It is critical to note that these kits have not been designed for isolating viral RNA, and performance of each kit varies. The user must consult the product-specific handbook or user manual. We strongly recommend using only dedicated RNA isolation products for SARS-CoV-2, such as those listed below:

Solutions authorized for use for COVID-19 testing in some regions (please check local regulations)

Syndromic Testing

QIAGEN multiplex syndromic testing support for SARS-CoV-2*

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN has developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge enables detection of the SARS-CoV-2 virus that causes COVID-19 in addition to 20+ other respiratory pathogens.*

Tailored oligonucleotides for SARS-CoV-2 detection

Updated April 27

In our effort to support the detection of the SARS-CoV-2 virus, OEM by QIAGEN has ramped up the production of SARS-CoV-2 specific primers and probes. We provide customized oligos defined by our customers, as well as those mentioned in protocols recommended by WHO and the CDC. To meet the high demands, we are currently prioritizing the orders of SARS-CoV-2 specific oligonucleotides. In addition, we have introduced pre-manufacturing of these oligonucleotides to enable quick supply and delivery. To order, please send your requests here.

The next generation of syndromic insights

Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights

To support the efforts of labs sequencing the SARS-CoV-2 virus on the front lines of the COVID-19 pandemic, QIAGEN is offering free temporary licenses to researchers worldwide involved with COVID-19 research and response.

For automated nucleic acid purification

*The number of targets/pathogens detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panels is different in different countries.

The QIAstat-Dx Respiratory SARS-CoV-2 Panels are intended for in vitro diagnostic use.

The US version of the QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use under Emergency Use Authorization Only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has not been FDA cleared or approved;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized by FDA under an EUA for use by authorized laboratories;
The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.